Cyclin-D1 over-expression represents one of several common alterations in the G 1 -S transition associated with malignancies. Conclusive evidences indicate that cyclin D1 is a proto-oncogene and the gene is amplified or rearranged in different tumour types. Since very little is known about aberratio
Cyclin D1 and cyclin E expression in malignant thyroid cells and in human thyroid carcinomas
β Scribed by Davide Lazzereschi; Laura Sambuco; Caterina Carnovale Scalzo; Annalisa Ranieri; Gabriella Mincione; Francesco Nardi; Giulia Colletta
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- French
- Weight
- 222 KB
- Volume
- 76
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## BACKGROUND. The cyclin D1 gene is amplified and/or overexpressed in several types of human cancer, including cancers of the breast, esophagus, head, and neck. However, the role of cyclin D1 in prostate cancer has not been previously studied in detail. METHODS. Six human prostate cancer cell lin
We analyzed the expression and amplification of cyclin D1 and CDK4 genes in ovarian carcinomas. Northern blot analysis revealed overexpression of cyclin D1 in 12 of 65 (18%) ovarian carcinomas while CDK4 was overexpressed in 7 of 48 cases (14%). None of the tumors showed amplification of any of the
Thyroid carcinomas no longer accessible to radio-iodide or TSH-suppressive T4 therapy, due to loss of thyroid-specific functions, might be sufficiently re-differentiated by retinoic acid (RA) to be treated by conventional methods again. To help evaluate the feasibility of RA re-differentiation thera
Cyclins are important in the regulatory system controlling cell cycle progression and overexpression or aberrant expression of G1 cyclins, as cyclin E, may result in an inadequate G1-S transition. In this study, the expression of cyclin E was analyzed in 12 human cell lines and 18 hematological mali
Cyclin-D1 (CD1) expression was analyzed in human mammary carcinomas by immunohistochemical (IHC) and flowcytometry (FCM) methods: 52.5% and 50% of cases were strong expressors of CD1 by IHC and FCM analysis respectively. The percentage of CD1-positive cells was especially high in node-negative (N Ψ